XARELTO®: Stroke risk reduction in patients with nonvalvular atrial fibrillation (NVAF)

PROVEN ONCE-DAILY,*
24-HOUR STROKE RISK REDUCTION1,2

*Taken with evening meal.

Demonstrated clinical outcomes in an obesity subgroup population and consistent real-world evidence in patients who have NVAF and morbid obesity3,4

For VTE prophylaxis in acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding.

   NVAF = nonvalvular atrial fibrillation; VTE = venous thromboembolism.